Shares of Israeli drug delivery specialist Entera Bio Ltd. (NASDAQ:ENTX) led the U.S. market March 11, in both percentage gain and volume, climbing 152.5% to $4.04 after a report that its oral parathyroid hormone candidate, EB-613, significantly boosted levels of P1NP, a biomarker indicating new bone formation vs. placebo at three months in an ongoing phase II osteoporosis study.
The skeleton undergoes continuous remodeling throughout life in response to diverse environmental stimuli. Osteoclasts, which are specialized cells on the bone surface, break down old bone tissue (in a process known as bone resorption) and build it back up. Dysregulation of osteoclast formation and function can lead to bone fragility, including osteoporosis, which is estimated to affect over 10 million people globally.
As expected, the FDA granted an approval for Amondys 45 (casimersen), a new Duchenne muscular dystrophy (DMD) therapy developed by Sarepta Therapeutics Inc.
RSS
